Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector.
COVID-19 vaccine
HLA-A2.1 transgenic mice
SARS-CoV-2
Syrian hamsters
T-cell epitopes
cross-protection
influenza virus vector
live attenuated influenza vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
18 Jul 2022
18 Jul 2022
Historique:
received:
31
05
2022
revised:
06
07
2022
accepted:
14
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
The COVID-19 pandemic emerged in 2020 and has caused an unprecedented burden to all countries in the world. SARS-CoV-2 continues to circulate and antigenically evolve, enabling multiple reinfections. To address the issue of the virus antigenic variability, T cell-based vaccines are being developed, which are directed to more conserved viral epitopes. We used live attenuated influenza vaccine (LAIV) virus vector to generate recombinant influenza viruses expressing various T-cell epitopes of SARS-CoV-2 from either neuraminidase (NA) or non-structural (NS1) genes, via the P2A self-cleavage site. Intranasal immunization of human leukocyte antigen-A*0201 (HLA-A2.1) transgenic mice with these recombinant viruses did not result in significant SARS-CoV-2-specific T-cell responses, due to the immunodominance of NP
Identifiants
pubmed: 35891306
pii: vaccines10071142
doi: 10.3390/vaccines10071142
pmc: PMC9318028
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Russian Science Foundation
ID : 21-75-30003
Références
Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2118312119
pubmed: 35561224
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Eur J Immunol. 2006 Oct;36(10):2671-80
pubmed: 16981179
J Leukoc Biol. 2021 Dec;110(6):1171-1180
pubmed: 34231935
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Vaccines (Basel). 2020 Apr 24;8(2):
pubmed: 32344618
Sci Bull (Beijing). 2022 Jul 15;67(13):1372-1387
pubmed: 35637645
J Microbiol. 2022 Mar;60(3):276-289
pubmed: 35157219
PLoS Pathog. 2022 Feb 10;18(2):e1009914
pubmed: 35143587
Vaccine. 2021 Oct 1;39(41):6019-6024
pubmed: 34531078
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Virol. 2001 Oct;75(19):8899-908
pubmed: 11533153
Exp Toxicol Pathol. 2004 Jul;55(6):413-31
pubmed: 15384248
Cell Mol Immunol. 2021 Dec;18(12):2588-2608
pubmed: 34728796
Cell Rep Med. 2022 Feb 25;3(3):100562
pubmed: 35474748
J Virol. 2012 Oct;86(19):10293-301
pubmed: 22787224
Science. 2021 Oct 08;374(6564):eabh1823
pubmed: 34465633
Expert Rev Vaccines. 2018 Nov;17(11):977-987
pubmed: 30365908
Vaccine. 2016 Apr 12;34(17):2008-14
pubmed: 26954467
Rev Med Virol. 2022 May 1;:e2359
pubmed: 35491495
Sci Immunol. 2020 Jul 17;5(49):
pubmed: 32680954
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Sci Rep. 2021 Jun 23;11(1):13164
pubmed: 34162945
Expert Rev Vaccines. 2020 Jan;19(1):43-55
pubmed: 31903816
Vaccine. 2014 Jun 12;32(28):3509-16
pubmed: 24795226
Sci Rep. 2017 May 19;7(1):2193
pubmed: 28526819
Virus Res. 2021 Oct 15;304:198508
pubmed: 34329696
Cell. 2021 Aug 19;184(17):4401-4413.e10
pubmed: 34265281
NPJ Vaccines. 2021 Feb 22;6(1):28
pubmed: 33619260
Nat Commun. 2019 Jun 28;10(1):2846
pubmed: 31253788
PLoS Pathog. 2021 Dec 29;17(12):e1010203
pubmed: 34965282
Front Genet. 2021 Jun 23;12:684152
pubmed: 34249101
PLoS One. 2022 Apr 25;17(4):e0266701
pubmed: 35468147
J Immunol. 2021 Jul 15;207(2):376-379
pubmed: 34193597
iScience. 2021 Nov 19;24(11):103353
pubmed: 34729465
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Front Immunol. 2022 Feb 22;13:835830
pubmed: 35273611
J Virol. 2021 Feb 24;95(6):
pubmed: 33443088
Virology. 2011 Apr 10;412(2):297-305
pubmed: 21315402
Nature. 2022 Jan;601(7894):617-622
pubmed: 34814158
Microorganisms. 2021 Mar 26;9(4):
pubmed: 33810549
Immunome Res. 2009 Jun 17;5:3
pubmed: 19534819
J Autoimmun. 2004 Sep;23(2):117-26
pubmed: 15324930
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Cell Rep. 2020 Dec 1;33(9):108454
pubmed: 33220791
Vaccine. 2010 Nov 23;28(50):8015-25
pubmed: 20934458
Bull Exp Biol Med. 2019 Mar;166(5):631-636
pubmed: 30903496
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Respir Crit Care Med. 2010 Feb 15;181(4):394-418
pubmed: 20130146
Viruses. 2021 Sep 05;13(9):
pubmed: 34578354
Viruses. 2021 Jul 29;13(8):
pubmed: 34452355
Int J Infect Dis. 2022 Jan;114:252-260
pubmed: 34800687
Vaccines (Basel). 2021 Sep 28;9(10):
pubmed: 34696201
Expert Rev Vaccines. 2021 Sep;20(9):1097-1112
pubmed: 34348561
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19408-13
pubmed: 19047637
Antiviral Res. 2019 Aug;168:9-17
pubmed: 31075351
Genes Dis. 2022 Jan;9(1):216-229
pubmed: 34222571
Antiviral Res. 2020 Oct;182:104864
pubmed: 32585323
J Immunol. 2021 Jun 1;206(11):2566-2582
pubmed: 33911008
Science. 2021 Jun 18;372(6548):1336-1341
pubmed: 34006597
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Front Immunol. 2022 Feb 24;13:827605
pubmed: 35281016
Int J Infect Dis. 2020 Oct;99:40-46
pubmed: 32721529
Hum Vaccin Immunother. 2021 Oct 3;17(10):3276-3280
pubmed: 34254894
Hum Vaccin Immunother. 2018;14(12):2964-2970
pubmed: 30024831
Lancet Infect Dis. 2016 Mar;16(3):303-10
pubmed: 26673391
Epidemiol Infect. 2021 Nov 04;149:e237
pubmed: 34732275
Cell Rep. 2021 Sep 7;36(10):109664
pubmed: 34450033
J Exp Med. 1992 Feb 1;175(2):481-7
pubmed: 1732413